NCT06743945

POLA-R-CHP in the First-line Treatment of Transformed DLBCL

A Prospective, Multicenter, Phase II Study of POLA-R-CHP in the First-line Treatment of Transformed DLBCL

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate efficacy and safety of POLA-R-CHP in the treatment of patients with transformed DLBCL.

Detailed description

Patients with transformed DLBCL lack standard treatment. We intend to conduct a prospective, multicenter, phase II study in order to evaluate efficacy and safety of POLA-R-CHP as first-line treatment of patients with transformed DLBCL.

Conditions

• Transformed Lymphoma

Interventions

Type	Name	Description
DRUG	POLA-R-CHP	Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin

Timeline

• Start date: 2025-02-17
• Primary completion: 2027-12-01
• Completion: 2029-12-01
• First posted: 2024-12-20
• Last updated: 2025-02-25

Locations

1 site across 1 country: China